Mechanisms of antimotion sickness drugs.

Abstract

UNLABELLED Eight subjects, male and female, were rotated using the step method to progressively increase the speed of rotation (+2 rpm) after every 40 head movements to a maximum of 35 rpm. The end-point for motion sickness was the Graybiel Malaise III total of symptoms short of frank nausea. The drug treatments were placebo, scopolamine 0.6 mg and 1 mg, scopolamine 0.6 mg/d-amphetamine 10 mg, scopolamine 1 mg/d-amphetamine 10 mg and amphetamine 10 mg. RESULTS Scopolamine increased tolerated head movements over placebo level by +81, scopolamine 1 mg + 183, d-amphetamine + 118, scopolamine 0.6/d-amphetamine + 165, and scopolamine 1 mg/d-amphetamine 10 mg + 201. DISCUSSION The drugs effective in preventing motion sickness are divided into those with central acetylcholine blocking activity and those which enhance norepinephrine activity. A combination of both of these actions produces the most effective antimotion sickness medications. CONCLUSIONS The balance between the acetylcholine and norepinephrine activity in the CNS appears to be responsible for motion sickness.

Statistics

050100150'94'97'00'03'06'09'12'15
Citations per Year

345 Citations

Semantic Scholar estimates that this publication has 345 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wood1987MechanismsOA, title={Mechanisms of antimotion sickness drugs.}, author={Colleen D Wood and Joseph E Manno and Michelle J Wood and Barbara R Manno and Helmut Redetzki}, journal={Aviation, space, and environmental medicine}, year={1987}, volume={58 9 Pt 2}, pages={A262-5} }